Ultrasound- and microwave-assisted preparation of lead-free palladium catalysts: effects on the kinetics of diphenylacetylene semi-hydrogenation

The effect of environmentally benign enabling technologies such as ultrasound and microwaves on the preparation of the lead-free Pd catalyst has been studied. A one-pot method of the catalyst preparation using ultrasound-assisted dispersion of palladium acetate in the presence of the surfactant/capping agent and boehmite support produced the catalyst containing Pd nanoparticles and reduced the number of pores larger than 4 nm in the boehmite support. This catalyst demonstrated higher activity and selectivity. The comparison of kinetic parameters for diphenylacetylene hydrogenation showed that the catalyst obtained by using the one-pot method was seven times as active as a commercial Lindlar catalyst and selectivity towards Z-stilbene was high. Our work also illustrated that highly selective Pd/boehmite catalysts can be prepared through ultrasound-assisted dispersion and microwave-assisted reduction in water under hydrogen pressure without any surfactant

Synthesis and biological evaluation of the first example of NO-donor histone deacetylase inhibitor

[Image: see text] The NO-donor histone deacetylase inhibitor 2, formally obtained by joining Entinostat 1, a moderately selective Class I histone deacetylases (HDACs) inhibitor, to a 4-(methylaminomethyl)furoxan-3-carbonitrile scaffold, is described and its preliminary biological profile discussed. This hybrid regulates Classes I and II HDACs. Nitric oxide (NO) released by the compound activates soluble guanylate cyclase (sGC), causing Class II nuclear shuttling and chromatin modifications, with consequences on gene expression. The hybrid affects a number of micro-RNAs not modulated by its individual components; it promotes myogenic differentiation, inducing the formation of larger myotubes with significantly more nuclei per fiber, in a more efficient manner than the 1:1 mixture of its two components. The hybrid is an example of a new class of NO-donor HDACs now being developed, which should be of interest for treating a number of diseases

Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors

HDAC inhibitors and NO donors have already revealed independently their broad therapeutic potential in pathologic contexts. Here we further investigated the power of their combination in a single hybrid molecule. Nitrooxy groups or substituted furoxan derivatives were joined to the α-position of the pyridine ring of the selective class I HDAC inhibitor MS-275. Biochemical analysis showed that the association with the dinitrooxy compound 31 or the furoxan derivative 16 gives hybrid compounds the ability to preserve the single moiety activities. The two new hybrid molecules were then tested in a muscle differentiation assay. The hybrid compound bearing the moiety 31 promoted the formation of large myotubes characterized by highly multinucleated fibers, possibly due to a stimulation of myoblast fusion, as implicated by the strong induction of myomaker expression. Thanks to their unique biological features, these compounds may represent new therapeutic tools for cardiovascular, neuromuscular and inflammatory diseases